Immunic, Inc. (IMUX) Operating income 2016–2025
Immunic, Inc. (IMUX) annual operating income history from SEC filings — each fiscal year as reported.
-$103.2MFY2025 · since FY2016: -$41.3M → -$103.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$103.2M | -5.3% |
| FY2024 | -$98.1M | +1.2% |
| FY2023 | -$99.2M | +17.0% |
| FY2022 | -$119.5M | -30.4% |
| FY2021 | -$91.7M | -87.2% |
| FY2020 | -$49.0M | -32.2% |
| FY2019 | -$37.0M | -208.7% |
| FY2018 | -$12.0M | +77.2% |
| FY2017 | -$52.7M | -27.6% |
| FY2016 | -$41.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IMUX financial trends
IMUX RevenueIMUX Net incomeIMUX Net marginIMUX Gross profitIMUX Gross marginIMUX Operating marginIMUX Operating cash flowIMUX Free cash flowIMUX Capital expendituresIMUX Return on equityIMUX Stock buybacksIMUX Dividends paidIMUX Total assetsIMUX Total liabilitiesIMUX Shareholders’ equityIMUX overview →